press 3 20 Oct 2021

HistoIndex and Galecto to Collaborate on Galecto's Phase 2a...

Date: 20 Oct 2021

HistoIndex, a global leading artificial intelligence digital pathology (AI-DP) provider, has announced a collaboration with Galecto, Inc., a biotechnology company focused on the development of novel treatments for fibrosis and cancer.

This collaboration expands HistoIndex's portfolio of fibrosis assessment outside of Nonalcoholic Steatohepatitis (NASH) and other liver diseases. The proprietary stain-free imaging technology, incorporated by Second Harmonic Generation (SHG) along with AI-based algorithms, will be utilized to analyze and quantify collagen-associated parameters as part of Galecto's Phase 2a trial for its oral LOXL2 inhibitor GB2064 in myelofibrosis.

Read More
press 3 18 Aug 2021

HistoIndex’s Stain-free AI-based Digital Pathology Incorpo...

Date: 18 Aug 2021

HistoIndex has announced an agreement with clinical-stage biotechnology company Sagimet Biosciences, where its integrated suite of stain-free imaging with AI-based fully quantitative and zonal analysis of fibrosis will play a role in Sagimet’s Nonalcoholic Steatohepatitis (NASH) Phase 2b multi-center, double-blind, randomized placebo-controlled trial (FASCINATE-2) as both secondary and exploratory efficacy endpoints.

The integrated AI stain-free platform, which comprises the Genesis®200 Second Harmonic Generation (SHG) imaging system and image analysis algorithms, will assess approximately 330 paired patient biopsies for secondary efficacy endpoints. 

Read More
press 3 25 Jun 2021

HistoIndex's AI-Based Digital Pathology Indicates Concomitan...

Date: 25 Jun 2021

HistoIndex's Second Harmonic Generation (SHG) stain-free digital pathology platform has shown marked reduction in liver fibrosis (overall, reduction in perisinusoidal fibrosis, as well as regression of fibrous septa) from baseline to end-of-treatment at 48 weeks, in patients with NASH participating in a Phase 2 FLIGHT-FXR study. The data from the analysis further illustrates the significance of the AI-based digital pathology platform in revealing fibrosis regression in patients treated with Tropifexor (TXR) and its relation to steatosis (liver fat) reduction.

The results of this study were presented at EASL's International Liver Congress™ 2021 (ILC 2021) entitled, "Digital Pathology with Artificial Intelligence Analyses Reveal New Dynamics of Treatment-induced Fibrosis Regression in Nonalcoholic Steatohepatitis". 

Read More
HistoIndex Stain free AI Digital Pathology TNBC Credits IMCB sm 25 Jan 2021

HistoIndex Explores the Clinical Utility of Stain-free AI Di...

Date: 25 Jan 2021

HistoIndex's stain-free AI digital pathology platform, incorporating Second Harmonic Generation (SHG), holds promise as a quantitative tool in the assessment of morphological and architectural changes in collagen fibers within the tumor-stromal microenvironment in patients with TNBC.

This will allow clinicians to better interpret the role of collagen remodeling in tumor progression and its prognostic value. On a larger scale, the tool may greatly aid existing and future TNBC studies that are currently exploring new therapies for targeted treatments.

Read More
press 3 15 Dec 2020

HistoIndex and Consortium Partners Awarded S$1.2M for the De...

Date: 15 Dec 2020

HistoIndex has joined INTErPRET-NAFLD, an international liver R&D collaboration aimed at developing an integrated precision AI diagnostics tool for High-Risk Nonalcoholic Fatty Liver Disease (NAFLD)

Led by the University of Edinburgh, the multi-centre collaboration was recently awarded with a S$1.2M (750,000 Euros) innovative research grant, which will support the collaborators' mutual goal of developing and validating a tool that can accurately identify NAFLD patients who are at a higher risk of progressing to NASH, which can lead to adverse outcomes such as the irreversible cirrhosis, liver cancer and premature death.

 

Read More
press 3 18 Nov 2020

HistoIndex's AI-Based Platform Demonstrates Zonal Quantifica...

Date: 18 Nov 2020

HistoIndex's Second Harmonic Generation (SHG) stain-free digital pathology platform for the automated quantitative assessment of histological features has shown promising analyses that indicate post-treatment improvements in fibrosis. This was stated at an Oral Presentation entitled, "Safety and Efficacy of Tropifexor in Patients with Fibrotic Nonalcoholic Steatohepatitis: 48-week Results from Part C of the Phase 2 FLIGHT-FXR Study", during AASLD's The Liver Meeting Digital Experience™ 2020.

HistoIndex's quantitative analyses revealed novel aspects of improvement of NASH fibrosis beyond the conventional scoring of liver biopsies for Tropifexor-treated patients. In addition, zonal quantification of fibrosis changes showed a fibrosis improvement in the intermediary area of Zone 2 for Tropifexor-treated patients compared with placebo.

Read More
Fibrous Septa Quantitative assessment of liver fibrosis HistoIndex Credits1 25 May 2020

HistoIndex's AI-based Digital Pathology Platform: A Validate...

Date: 25 May 2020

Singapore medtech company HistoIndex's AI-based stain-free digital pathology platform has long been established as a suitable tool for global clinical guidelines that outline the assessment, prevention and treatment of Chronic Hepatitis B (CHB) infections.

In the latest edition of China's Guidelines for the Prevention and Treatment of Chronic Hepatitis B, the digital pathology platform was recommended for use in providing an automated and quantitative analysis of the liver's morphological characteristics in unstained liver biopsies with high repeatability and accuracy.

Read More
HistoIndex qFIBS 2 1k 10 Nov 2019

qFIBS Demonstrates Suitability for Nonalcoholic Steatohepati...

Date: 10 Nov 2019

qFIBS, a novel automated algorithm developed by HistoIndex, has been shown to accurately distinguish different grades and stages of histological NASH features with a continuous measurement approach. This was highlighted in an international, multicenter collaborative study conducted by pathologists and hepatologists from China, Singapore, Europe and United States.

“In clinical trials today, we depend on the ability to measure critical NASH liver biopsy characteristics especially in determining the extent of fibrosis and steatosis at the various regions of the biopsy, which is very important in assessing post-treatment responses. To assist pathologists in their assessments, it is imperative for pharmaceutical and biotech companies to consider working with a fully quantifiable tool such as qFIBS to provide accurate, standardized and consistent data in clinical trials.” - Dr Stephen Harrison, Medical Director of Pinnacle Clinical Research and President of Summit Clinical Research, and co-author of the multicenter study.

Read More
HistoIndex NASH Preclinical 26 Oct 2019

HistoIndex Announces Global Partnerships to Expand AI-Based...

Date: 26 Oct 2019

The Singapore-based company has fostered partnerships with pharmaceutical and biotech companies, Contract Research Organizations (CROs), academia and government-linked research institutes in empowering NASH drug discovery.

"We are very excited to extend our AI-based SHG platform to preclinical studies to help companies with drug discovery programs select promising lead candidates for further optimization and subsequent clinical development. Our SHG image analysis platform has already been used to analyze the efficacy of a series of promising drug candidates for NASH within various animal models commonly-used by the industry, and we believe these preclinical partnerships will help drive the adoption of our platform significantly." - Dr Poon Thong Yuen, Chief Executive Officer of HistoIndex. 

Read More
LITMUS Prof Quentin Anstee in lab grid 20 Aug 2019

[By Newcastle University] LITMUS – Progress towards diagno...

Date: 20 Aug 2019

Picture Credits: Newcastle University

HistoIndex Joins LITMUS Consortium of Partners to Develop, Validate and Qualify Better Biomarkers for NAFLD Testing.

- A pioneering European research project, designed to develop new diagnostic tests to assess patients with Non-Alcoholic Fatty Liver Disease (NAFLD) has expanded giving access to more patients.
- Incorporating several new partners also enables access to even more state-of-the art technologies.
- HistoIndex Joins LITMUS Consortium of Partners to Develop, Validate and Qualify Better Biomarkers for NAFLD Testing.

Read More

1 2